Conclusion
neutropenia
ADVERSE EVENTS, CERVICAL CANCER, NEUTROPENIA
Prophylactic use of PEG-rhG-CSF during chemoradiotherapy for cervical cancer can effectively prevent neutropenia and its related adverse events. PEG-rhG-CSF use may be an effective strategy to guarantee continuous radical chemoradiotherapy for cervical cancer by ensuring the designed time and dose of chemotherapy and an uninterrupted radiotherapy. This result is worth being further proven by a phase III randomized prospective study.This study was supported by the National Natural Science Foundation of China Fund (81872699).Conflict of interest: Authors declare no conflicts of interest.Funding: This study was supported by the National Natural Science Foundation of China Fund (81872699).